Table 1.

Demographics and clinical characteristics^*

	LT (n=83)	NHANES controls (n=235)	p
Age at visit (years)	15.6 ± 4.8	16.6 ± 4.1	0.11
Female	45%	43%	0.89
Race/Ethnicity
White	27%	27%	0.95
Black	9%	9%
Hispanic	43%	43%
Asian	13%	13%
Other/Multi-racial	8%	8%
AST (IU/L)	51 ± 73	25 ± 11	0.002
ALT (IU/L)	62 ± 102	22 ± 18	<0.001
GGT (IU/L)	65 ± 204	17 ± 19	0.03
Total bilirubin (mg/dL)	1.0 ± 0.7	0.8 ± 0.3	0.002
Creatinine (mg/dL)	0.65 ± 0.23	0.71 ± 0.18	0.04
Years since transplant	11.2 ± 5.7
Transplant indication¶
Biliary atresia	33%
Metabolic disease	17%
Acute liver failure	12%
Cholestatic conditions	6%
Tumor	2%
Other	30%
Glucocorticoids at visit	5%	0.4%	0.006
CNI
Tacrolimus	80%
Cyclosporine	10%
Not on CNI	10%
Tacrolimus trough at visit (n=66, μg/L)	4.4 ± 2.2
Mean recent tacrolimus trough† (n=66, μg/L)	4.8 ± 2.2
Cyclosporine trough at visit (n=8, μg/L)	75 ± 52
Mean recent cyclosporine trough† (n=8, μg/L)	96 ± 63

^*Data represents proportion or mean ± SD. McNemar’s chi-squared test for categorical variables, t-test with unequal variances for continuous variables.

^¶Metabolic disease includes alpha-1-antitrypsin deficiency, Crigler-Najjar syndrome, cystic fibrosis, glycogen storage disease, inborn errors in bile acid metabolism, neonatal hemochromatosis, primary hyperoxaluria, tyrosinemia, urea cycle defects, and Wilson’s disease. Cholestatic conditions includes Alagille syndrome, Byler disease, progressive intrahepatic cholestatic syndromes, total parenteral nutrition cholestasis, sclerosing cholangitis, and idiopathic cholestasis. Other diagnoses include congenital hepatic fibrosis, Budd-Chiari syndrome, autoimmune hepatitis cirrhosis, drug toxicity, hepatitis C cirrhosis, and unknown cirrhosis.

^†Mean of 3 most recent trough levels prior to study visit.